Journal Mobile Options
Table of Contents
Vol. 136, No. 3, 2005
Issue release date: March 2005
Int Arch Allergy Immunol 2005;136:281–286

Quality of Life during Pollen Season in Patients with Seasonal Allergic Rhinitis with or without Asthma

Laforest L. · Bousquet J. · Pietri G. · Sazonov Kocevar V. · Yin D. · Pacheco Y. · van Ganse E.
aPharmacoepidemiology Unit, EA3091 CHU Lyon-Sud, Pierre-Bénite, bDepartment of Respiratory Medicine, CHU, Montpellier, France; cRutgers University, Piscataway, N.J., dMerck & Co., Inc., Whitehouse Station, N.J., USA; eDepartment ofRespiratory Medicine, EA3091 CHU Lyon-Sud, Pierre-Bénite, France

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objectives: We studied the evolution of generic and rhinoconjunctivitis-specific quality of life (QOL) during pollen season in patients with isolated seasonal allergic rhinitis (SAR) and those with asthma and concomitant SAR (AS+SAR). Generic QOL between groups was also compared at pollen peak. Methods: A prospective cohort study was conducted in Southern France in 2002. Outpatients aged 18–60, regularly visiting respiratory physicians for SAR, were recruited before the grass (grass cohort) or ragweed pollination period (ragweed cohort). Before the pollination period (baseline) and at peak pollination, patients completed French versions of the Mini Rhinoconjuctivitis Quality of Life Questionnaire (Mini-RQLQ) and physical and mental Short Form-12 (SF-12) scores (PCS and MCS) to determine rhinoconjunctivitis and generic QOL. Results: Totals of 83 and 52 patients were included in the SAR and AS+SAR groups, respectively (mean age = 35.4; 56.4% females). Mini-RQLQ scores indicated slightly worse QOL in the A+SAR group at inclusion, which significantly deteriorated at the time of pollen peak, both in the SAR (p < 0.0001) and AS+SAR groups (p = 0.003). In univariate analysis, significantly higher SF-12 PCS (meaning better QOL) were observed at pollen peak in the SAR compared with the AS+SAR group (p = 0.0008), while the difference for SF-12 MCS was more limited (p = 0.05). Results were confirmed in multivariable analyses adjusting for gender, allergy medication use at pollen peak, cohort of inclusion (grass/ragweed) and comorbid conditions. Conclusions: Significant deterioration in rhinoconjunctivitis-specific QOL was observed through the pollination period in patients with SAR and AS+SAR. At pollen peak, AS+SAR patients experienced significantly worse physical functioning than patients with SAR alone.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Corren J: Allergic rhinitis and asthma: How important is the link? J Allergy Clin Immunol 1997;99:S781–S786.
  2. Leynaert B, Neukirch F, Demoly P, Bousquet J: Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol 2000;106:S201–S205.
  3. Thompson AK, Juniper E, Meltzer EO: Quality of life in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2000;85:338–347.
  4. Meltzer EO: Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol 2001;108:S45–S54.

    External Resources

  5. Ware J Jr, Kosinski M, Keller SD: A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220–233.
  6. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN: Development and validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire. Clin Exp Allergy 2000;30:132–140.
  7. Juniper EF: Measuring health-related quality of life in rhinitis. J Allergy Clin Immunol 1997;99:S742–S749.

    External Resources

  8. Guyatt GH, Feeny DH, Patrick DL: Measuring health-related quality of life. Ann Intern Med 1993;118:622–629.
  9. Leynaert B, Neukirch C, Liard R, Bousquet J, Neukirch F: Quality of life in allergic rhinitis and asthma. A population-based study of young adults. Am J Respir Crit Care Med 2000;162:1391–1396.
  10. Juniper EF: Quality of life in adults and children with asthma and rhinitis. Allergy 1997;52:971–977.
  11. Price DB, Zhang Q, Sazonov Kocevar V, et al: Effect of concomitant allergic rhinitis on asthma-related hospitalizations, general practitioner visits, and drug costs among adults in the United Kingdom podium. Clin Exp Allergy, in press.
  12. Corren J, Manning BE, Thompson SF, Hennessy S, Strom BL: Rhinitis therapy and the prevention of hospital care for asthma: A case-control study. J Allergy Clin Immunol 2004;113:415–419.
  13. Chang S, Long S, Leahy M, Crown WH: Health care expenditures of patients with comorbid allergic rhinitis and asthma (abstract PAA7). Value Health 2004;7:310.
  14. Crystal-Peters J, Neslusan C, Crown WH, Torres A: Treating allergic rhinitis in patients with comorbid asthma: The risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol 2002;109:57–62.
  15. Adams RJ, Fuhlbrigge AL, Finkelstein JA, Weiss ST: Intranasal steroids and the risk of emergency department visits for asthma. J Allergy Clin Immunol 2002;109:636–642.
  16. Allergic Rhinitis and its Impact on Asthma (ARIA):
  17. Price DB, Swern AS, Tozzi CA, Philip G, Polos P: Additional benefit of montelukast for asthma in patients with both asthma and allergic rhinitis: Analysis from the COMPACT trial. Abstracts of the World Allergy Organization Congress – XVIII ICACI, Vancouver, Canada, 7–12 September 2003. Allergy Clin Immunol Int – J World Allergy Org 2003;suppl 1:29.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50